In high-level reshuffle, Roche gives James Sabry the global reins on deal-making — overseeing pRED and gRED
In the 9 years since Roche bought up all of Genentech, the Swiss pharma giant has been careful to leave its legacy R&D group pRED …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
